GeneDx Holdings Corp. (NASDAQ:WGS) Stock Rated “Moderate Buy” by Wall Street Analysts

Shares of GeneDx Holdings Corp. (NASDAQ:WGS) have received an average rating of “Moderate Buy” from the nine analysts that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $90.86.

Several equities research analysts have weighed in on WGS shares. Guggenheim upped their target price on GeneDx from $74.00 to $83.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. BTIG Research restated a “buy” rating and set a $90.00 price target on shares of GeneDx in a research note on Tuesday, August 4th. Weiss Ratings restated a “sell (d)” rating on shares of GeneDx in a report on Monday, November 2nd. Zacks Research lowered shares of GeneDx from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 9th. Finally, TD Cowen reiterated a “buy” rating on shares of GeneDx in a report on Wednesday, July 15th.

Insider Activity

In related news, CEO Katherine Stueland sold 10,501 shares of GeneDx stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total transaction of $1,025,002.61. Following the transaction, the chief executive officer directly owned 115,476 shares of the company’s stock, valued at $11,271,612.36. This trade represents a 8.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Kevin Feeley sold 3,728 shares of GeneDx stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total transaction of $363,890.08. Following the transaction, the chief financial officer directly owned 44,945 shares in the company, valued at approximately $4,387,081.45. The trade was a 7.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 19,206 shares of company stock valued at $1,808,056. Company insiders own 25.17% of the company’s stock.

Hedge Funds Weigh In On GeneDx

Several institutional investors and hedge funds have recently added to or reduced their stakes in WGS. Strs Ohio raised its stake in GeneDx by 8.7% during the 1st quarter. Strs Ohio now owns 2,500 shares of the company’s stock valued at $161,000 after acquiring an additional 200 shares during the last quarter. Pictet Asset Management Holding SA lifted its position in GeneDx by 12.9% during the 1st quarter. Pictet Asset Management Holding SA now owns 3,300 shares of the company’s stock worth $212,000 after acquiring an additional 378 shares during the period. Swiss National Bank lifted its position in GeneDx by 1.0% during the 1st quarter. Swiss National Bank now owns 40,000 shares of the company’s stock worth $2,569,000 after acquiring an additional 400 shares during the period. Fifth Third Bancorp acquired a new stake in GeneDx during the 1st quarter worth approximately $31,000. Finally, Keebeck Wealth Management raised its stake in shares of GeneDx by 13.5% during the first quarter. Keebeck Wealth Management now owns 4,310 shares of the company’s stock worth $277,000 after purchasing an additional 513 shares during the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

GeneDx News Summary

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: GeneDx reported Q3 earnings of $0.28 per share, above the $0.07 consensus estimate, and revenue of $123.1 million, slightly ahead of expectations. Article: GeneDx tops Q3 earnings and revenue estimates
• Positive Sentiment: Management’s focus on reimbursement rates, operational efficiency and AI-driven billing could support a transition to sustained profitability. One analysis also sees strong revenue growth continuing through 2027. Article: GeneDx Q3 earnings indicate transition to sustained profitability
• Negative Sentiment: Reports that GeneDx lowered its growth targets may weigh on investor expectations, despite the quarterly beat. Article: GeneDx shares tumble on lowered growth targets
• Negative Sentiment: EPS was below the year-ago $0.49, and the company continues to report a negative net margin, underscoring that durable profitability is not yet assured.

GeneDx Price Performance

GeneDx stock opened at $65.72 on Thursday. GeneDx has a 12-month low of $32.21 and a 12-month high of $170.87. The company has a current ratio of 3.30, a quick ratio of 3.06 and a debt-to-equity ratio of 0.40. The firm has a 50-day moving average price of $76.42 and a 200-day moving average price of $71.15. The firm has a market capitalization of $1.96 billion, a PE ratio of -18.05 and a beta of 2.00.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Monday, November 9th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.21. The company had revenue of $123.10 million during the quarter, compared to analysts’ expectations of $122.93 million. GeneDx had a negative net margin of 23.41% and a positive return on equity of 4.12%. During the same period in the previous year, the company earned ($0.27) EPS. As a group, equities research analysts forecast that GeneDx will post -0.41 EPS for the current year.

GeneDx Company Profile

GeneDx is a genomic testing company focused on helping clinicians diagnose rare and inherited conditions. Its services include whole exome and whole genome sequencing, along with other genetic tests and clinical interpretation of results.

The company’s testing is used by healthcare providers to support diagnosis and care decisions, particularly for patients with suspected rare genetic disorders. GeneDx also offers testing related to hereditary cancer risk.

Founded in 2000 by researchers with experience at the National Institutes of Health, GeneDx has developed its business around applying genomic information in clinical care.